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ALPHA MANGOSTIN AS A CHEMOPROTECTANT
ABSTRACT
Breast carcinoma is the most frequently diagnosed cancer among women and causes over
400,000 deaths each year worldwide. Current treatments such as chemotherapy are not
selective for cancerous tissues but are destructive to normal tissues as well. This causes a
range of side effects including pain, nausea, hair loss, weakness, and more. Inactivation
of p53 is a very common mutation within human cancer cells. The ability to activate the
p53 pathway which protects cells from tumor formation is lost in 50% of cancers. Due to
the prevalence of this mutation, p53 is a uniquely valuable target for applied research.
Alpha mangostin is an extract from a southeast Asian fruit, Garcinia mangostana. It has
potential to be an effective p53 activator in which the small molecule disrupts the binding
of p53 to MDM2, a negative regulator, inducing the p53 cascade which results in cell cycle
arrest for low level stressors. This protects the cells from paclitaxel, a chemotherapy agent
that only kills actively dividing cells. Here, we hypothesized that alpha mangostin protects
wild-type, but not p53 (-/-), MCF10A breast cancer cells from the chemotherapeutic agent
paclitaxel. When MCF10A wild-type cells were cotreated with alpha mangostin and
paclitaxel, alpha mangostin exhibited a protective effect on the cells. However, when
MCF10A P53 knockout cells were treated with alpha mangostin, cell viability decreased
indicating a loss of protective effect in the p53 distressed cancer cells. These results
further support treatments that target chemoprotection via p53 pathway in wild-type
cells and the use of alpha mangostin warrants further study.
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LITERATURE REVIEW
Breast Carcinoma & Treatments
The development of cancer is a multistep process that involves complex
interactions between host and tumor tissue. The process involves oncogene activation as
well as immunosuppression, leading to uncontrolled cell growth despite damaged DNA
(Wang 2010). Genome instability contributes to cancer development due to mutations in
DNA damage response pathways, which are mediated through the tumor suppressor p53
(Reinhardt & Schumacher, 2012).
Breast carcinoma is the most frequently diagnosed cancer among women and
causes over 400,000 deaths yearly worldwide (Walerych, Napoli, Collavin, & Del Sal, 2012).
Metastasis accounts for a large majority of the deaths that result from breast cancer,
mostly to lymph nodes, lungs, and bones. The complexity of cancer leads to difficulties in
treatment. Many of these difficulties are due to the nonselective nature of the treatment
which cause cell toxicity in noncancerous cells. Treatment plans are dependent on the
stage and characteristics of the cancer, as well as the age, menopausal status, and risk
benefit analysis associated with each option. Based on a study in 2017, stage I and II
patients most often receive breast conserving surgery. Stage III patients most often
receive a mastectomy, radiation therapy, as well as chemotherapy with a five-year
survival rate of 72%. Stage IV patients most often receive radiation therapy and or
chemotherapy with a five-year survival rate of about 22% (American Cancer Society,
2017).
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In order to delay the progression of breast cancer and increase the longevity of
patients, less toxic yet effective chemotherapeutic agents are needed to limit the
debilitating side effects while also improving outcomes (Shibata et al., 2011). These side
effects include pain, lymphedema, musculoskeletal symptoms, bone loss and
osteoporosis, heart problems, new cancers, blood clots, infertility, and loss of memory
and cognitive function. (American Cancer Society, 2017).
Currently, conventional treatments such as radiation, chemotherapy, and surgery
have not been entirely effective against the high incidence and low survival rates of breast
cancer due to its complex nature (Moongkarndi et al., 2004). Research has established
that combinations of drugs are more effective than one drug alone for the treatment of
early-stage breast cancer. An example of such treatment is Trastuzumab, a monoclonal
antibody that directly targets the human epidermal growth factor 2 (HER2) protein.

Figure 1. Various outcomes of the p53 pathway. Different causes, such as those of mild
physiological stress or severe stress, interrupt the mdm2 and p53 binding and result in
various outcomes such as DNA repair, growth arrest, apoptosis, and more (Vogelstein,
Hughes, Kimmel, & Cancer, 2013).
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When combined with chemotherapy, this treatment was found to reduce the risk
of recurrence by 52% and death by 33% for patients who overproduce the growth
promoting protein HER2/neu (American Cancer Society, 2017). This leads the scientific
community to search for other potential therapeutic approaches including drug
combinations to treating this malignancy and many other cancers that continue to evade
conventional treatments.

P53 Gene & Cascade
The main function of p53 is to
promote genetic stability and prevent
the formation of tumors. When a cell
is under stress, it induces cell death
through apoptosis for severe stress or
cell arrest and subsequent DNA repair
for mild stress in order to prevent
malignant growth. Under normal
conditions, p53 levels are low and the
binding to mouse double minute 2
homolog (MDM2) targets it to the
proteasome for rapid degradation
and inhibition of its transcriptional
activity (Burgess et al., 2016).

Figure 2. The p53 Cascade. This figure is
a simple representation of a cell’s
response to stress that result in DNA
damage. The first step is phosphorylation
of p53 to affect its binding to mdm2. This
process also includes a key player in the
process, p21, which is a Cdk inhibitor.
The end result is an inactivation of the
G1.S-Cdk and D-Cdk complex with p21.
(Vogelstein, Hughes, Kimmel, & Cancer,
2013).
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When stress occurs, binding to the regulatory protein MDM2 is disrupted due to
P53 phosphorylation, which leads to p53 accumulation and subsequent transcription of
numerous genes, including the gene that encodes the cyclin-dependent kinase inhibitor
(CKI) protein p21. P21 binds and inactivates G1/S-Cdk complexes, arresting the cell in G1
for DNA repair.
P53 Mutation & Treatments
Inactivation of p53 is a very common feature of human cancer cells (Lane, Cheok,
& Lain, 2010). About 50% of adult cancer has p53 inactivated (by mutation or deletion)
while the other 50% have suppressed wild-type p53 function (Choong, Yang, Lee, & Lane,
2009). On average, p53 is mutated in 20% of tumors in breast cancer. Though the
frequency of mutation is lower in breast cancer cells, p53 inactivation has been seen in
some breast cancers without a mutation. The pathway has been shown to be affected by
alterations in upstream regulatory proteins and downstream p53-induced proteins
(Gasco, Shami, & Crook, 2002). In breast cancer, this mutation is associated with a more
aggressive disease and worse overall survival according to several studies (Gasco et al.,
2002).
The ability to activate the p53 pathway which protects cells from tumor formation
is lost in cells with p53 mutations. Most of these mutations occur as a result of a
substitution of single amino acids in the central region of the p53 protein, which causes
many variants (Walerych et al., 2012). Indeed, rapid malignant cell growth which leads to
many different cancer types often involves a defective p53 gene, which is the
transcriptional activator that works to suppress tumors in normal tissues (Muller &
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Vousden, 2014). In breast cancer, mutant p53 is involved in many processes associated
with cancer development such as early tumorigenesis, tumor growth and development,
and metastasis (Walerych et al., 2012). In clinical practice, molecular pathological analysis
of the tumors of the structure and expression and constituents of the p53 pathway is
likely to have value in diagnosis, in prognostic assessment and, ultimately, in treatment
of breast cancer (Gasco et al., 2002).
Chemotherapy and Mechanism of Chemoprotection
Chemotherapy induces many adverse effects in patients because of normal cell
toxicity, resulting at least in part from p53 activation and apoptosis induction in normal
proliferating cells/tissues, such as bone marrow, lymphoid organs, hair follicles, and
epithelium lining of the small intestine (Wang & Sun, 2010). An important aspect of
chemotherapy is it kills actively dividing cells. In particular, paclitaxel inhibits microtubule
function, which kills cells as they enter mitosis (Blagosklonny, 2002). Microtubules are
essential to the process of mitosis as they separate chromosomes to opposite sides of the
cell during anaphase. When paclitaxel inhibits the ability for the chromosomes to be
separated during the division process, the cell is inactivated and eventually is killed.
Therefore, wild-type cells treated with the p53 activator are arrested in G1 and do not
enter into mitosis and therefore the chemotherapy selectively kills p53-deficient cancer
cells. This mechanism can be experimentally controlled with the use of p53 activators to
arrest p53 wild-type cells and protect against the harmful effects of chemotherapeutic
agents on noncancerous cells.
P53 Activator Current Research
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Due to the prevalence of this mutation, p53 is a uniquely valuable target for
applied research (Vogelstein et al., 2013). Therefore, much research has gone into both
therapeutic strategies to restore mutant to wild-type p53 and pretreatment of cancer
cells with p53 activators, that arrest noncancerous p53-normal proliferating cells without
impacting the cell cycle of cells with a p53 mutation, thus allowing for selective killing of
cancerous cells.
Current research on this type of treatment has led to the discovery of small
molecules that directly or indirectly activate p53. Some p53 activation has been achieved
in the clinic. The most advanced of these are the p53 MDM2 interaction inhibitors. The
first class of small molecule mdm2 inhibitors discovered was nutlin-3a, which binds to the
hydrophobic cleft in the N-terminus of mdm2, preventing its association with p53 and
initiating the cascade. Since this discovery of nutlin-3a, many more related compounds
have been tested, some of which have now made it to the preclinical stage. This stage will
better assess the biological effects and toxicity of the treatment to patients (Burgess et
al., 2016). As research continues and understanding of p53 response increases,
development will continue allowing for powerful drug combinations that may increase
the selectivity and safety of chemotherapy, by selective protection of normal cells and
tissue (Lane et al., 2010).
Alpha Mangostin as a Chemoprotectant
Alpha mangostin is a p53 activator that is isolated from the carp of the Garcinia
mangostana (Mangosteen fruit), which is native to Thailand and traditionally used for
antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, and antiviral
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medicinal purposes (Pedraza-Chaverri, Cárdenas-Rodríguez, Orozco-Ibarra, & Pérez-Rojas,
2008). This extract is known to inhibit the binding of p53 to MDM2, a negative regulator
of p53.
In one study in 2011, alpha mangostin was used to reduce tumor growth and
lymph node metastasis in an immunocompetent xenograft model of metastatic
mammary cancer with a p53 mutation. The study showed that treatment with 20
mg/kg/day alpha mangostin resulted in prolonged survival rates and increased inhibition
of tumor growth and lymph node metastasis (Shibata et al., 2011). This reveals that this
extract at high concentrations can potentially be a successful treatment for p53 mutated
cancer types. Meanwhile, at lower concentrations, alpha mangostin has the potential to
act as a chemoprotectant to wild-type cells. One study tested the chemoprotection of
alpha mangostin on wild-type BHK cells. The results supported the hypothesis that the
alpha mangostin can be used to protect cells from the cytotoxic effects of chemotherapy
(Wojciechowski, 2017). However, the effect on breast cancer cell lines at low
concentrations is not known. Here, this research seeks to determine whether or not the
alpha mangostin pretreatment would be an effective strategy for chemoprotection of
wild-type cells by testing whether or not the cancer cells are also protected. If the data
indicate that the cancerous cells are not protected, this p53 activator could potentially be
a successful pretreatment before chemotherapy for selective cancer killing. I hypothesize
that alpha mangostin, a p53- dependent chemoprotectant, protects wild-type cells, but
not those with a p53 mutation from the chemotherapeutic agent paclitaxel.
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MATERIALS AND METHODS
Culturing of MCF10A Cells
Cell culture protocol was based on the ATCC© Thawing, Propagating, and
Cryopreserving Protocol (“Thawing, Propagating, and Cryopreserving Protocol: MCF10AJSB Breast epithelium,” 2012). MCF10A p53 Wild-type and p53 knockout (-/-) human
breast cancer cells were cultured in Dulbecco’s Modified Eagle’s Medium supplemented
with Cholera Toxin from V. cholera, Insulin solution, Epidermal Growth Factor, 50 uM
Hydrocortisone Solution, and Horse Serum at 370 C. PBS was used to rinse the wells before
lifting. Trypsin-EDTA solution was used to lift cells.
Determining the Toxicity of Alpha Mangostin and Paclitaxel
Cells were treated at various levels of alpha mangostin and paclitaxel to create a
dose response curve and toxicity curve and determine workable concentrations for the
dual treatment experiments. For the dual treatment, cells were treated with various
concentrations of alpha mangostin, ranging from 0-.25 uM, for 24 hours followed by a
24 hour dual treatment of alpha mangostin and 15 nM paclitaxel.
Differentiating between Viable, Apoptotic, and Necrotic Cells
Cells were stained with Hoechst, YO-PRO 1, and Propidium Iodide to
differentiate between viable, apoptotic, and necrotic cells. Data was collected on cell
viability using differential fluorescent staining. The differences were shown through
fluorescent microscopy with Hoechst, Propidium Iodide, and YO-PRO-1 stains. The
Hoechst stain only stains normal healthy cells. The next two, Propidium Iodide and YOPRO-1, only stains necrotic and apoptotic cells, respectively. Through these three stains,
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I will be able to only evaluate the attached cells for comparison. Quantitatively, the cells
stained with Hoechst stain were used for the results section. However, the two other
stains are shown in the figures with photos. Representative pictures at 10x were taken
blindly by a professor in order to eliminate bias and counted using the fluorescent cell
counting program.
Development and Use of Cell Counting Program
The program used to count the cells was developed by Evan Dexter using
Microsoft Visual Studio in C# language. The code for this program is shown in Appendix
I. It works by use of an algorithm that examines the color values of the pictures'
pixels. Pixels with high values of the color being counted are flagged as potential cell
locations. Various user-controlled parameters are then used to refine the number of
cells from the initial list. Changing the parameters makes it possible to count the
number of cells for different types of cells and conditions. The resulting count is
displayed to the user as both a sum total and a marker on each cell location (Dexter
2019).
RESULTS
Data shown in the results section come from representative photos taken at
100x on a fluorescent microscope and analyzed using a double-blind method. Typical
methods such as the cell hemocytometer were not able to be used due to difficulties
lifting the cells without killing them. Therefore, developed a program that would count
representative photos to have an idea of cell viability in each of the treatment wells
(appendix). Viable cells were counted as indicated by the blue Hoechst stain.
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Concentration ranges for toxicity curves and dose response curves were based upon
previous research using these treatments with baby hamster kidney cells
(Wojciechowski, 2017).
Single Treatment Results for Wild-Type Cells (p53 Pathway intact)
We first wanted to determine the effect of the chemotherapeutic drug,
paclitaxel, on the MCF10A wildtype cells. This procedure allowed for the determination
of a concentration that would be suitable for dual treatment with alpha mangostin.
A

B

C

D

Figure 3. Fluorescent Microscopy of MCF10A Wild-Type Cells after
treatment with Paclitaxel (A is the control, B is 10 nM, C is 25 nM, and D
is 35 nM). The orange markers on the photos indicate that the cell was
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counted using the fluorescent cell counting program. Increase in
concentration led to a decrease in live cell count.

Increasing concentrations of alpha mangostin caused a decrease in the number
of cells in the well (Figures 3 & 4). There were not many floating dead cells in the wells
which indicate that the decrease in cell number was likely due to cell cycle arrest. The
control well had a variable number of cells in each well, as indicated by the large error
bars in Figure 4. If experimental error did not have an effect on the results of the control
well, then very low concentrations of paclitaxel had a mitogenic effect on the wild-type
MCF10A cell line. The chosen concentration of paclitaxel for the dual treatment was 15
nM as higher concentration did not give a sufficient number of cells to allow for variable
cell counts with lower standard error.
3500
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2500
2000
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1000
500
0
0
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10
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25

35

Paclitaxel Concentration (nM)

Figure 4. Wild-Type MCF10A Paclitaxel Toxicity Curve. Wild-Type MCF10A Paclitaxel
Toxicity Curve. Cells were treated with concentrations ranging from 0-35 nM for 24
hours and the cell count per field of view was recorded per well. The 5, 10, and 15 nM
concentration of Paclitaxel had a mitogenic effect on the cells with toxicity beginning at
25 nM.
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We next sought to determine the effect of alpha mangostin on cell viability for
the wild-type MCF10A cells. This experiment was also done in order to determine an
acceptable range for the dual treatment for this cell line with the chemotherapeutic
agent, paclitaxel.
A

B

C

D

Figure 5. Fluorescent Microscopy of MCF10A Wild-Type Cells after
treatment with Alpha Mangostin (A is the control, B is 0.05 μM, C is 0.15
μM, D is 0.25 μM). The orange markers on the photos indicate that the
cell was counted using the fluorescent cell counting program. Increase in
concentration led to a decrease in live cell count.
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The MCF10A wild-type cells responded in a dose dependent manner (Figure 5 &
6). In addition to the control, varying concentrations ranging from 0.05 to 0.25 were
used because it gave a suitable range that had variable cell counts.
3000
2500

Cell Count

2000
1500
1000
500
0
0

0.05

0.1

0.15

0.2

0.25

Alpha Mangostin Concentration (uM)

Figure 6. Wild-Type MCF10A Alpha Mangostin Dose Response Curve. Cells were treated
with varying concentrations of alpha mangostin for 24 hours and counted using the
fluorescent cell counting program.

Dual Treatment Results for Wild-Type Cells (p53 Pathway intact)
The final experiment for the wild-type cells was the dual treatment with alpha
mangostin for 24 hours followed by a combination of alpha mangostin and paclitaxel for
another 24 hours.
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Figure 7. Wild-Type MCF10A Alpha Mangostin & Paclitaxel Dual Treatment. Cells were
treated with varying concentrations of alpha mangostin for 24 hours and counted using
the fluorescent cell counting program.
Cells treated with alpha mangostin alone and those cotreated with paclitaxel
yielded similar cell counts (Figure 7). While these results indicate a negligible effect of
alpha mangostin as a chemoprotectant, we also observed a wide variety of
experimental error as will be discussed further below.

A

B

Figure 8. Fluorescent Microscopy of Wild-Type MCF10A Paclitaxel
Treatment vs Dual Treatment with Alpha Mangostin. A is the paclitaxel
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only treatment and B is the alpha mangostin paclitaxel dual treatment.
The orange markers on the photos indicate that the cell was counted
using the fluorescent cell counting program.

Single Treatment Results for MCF10A p53 (-/-) Cells
P53 is known to be an important regulator of cell cycle arrest and as noted above
is often absent in numerous cancers. We therefore wanted to determine the role of a
chemoprotectant such as alpha mangostin on p53 knockout cells (Figures 9 & 10). The
concentration range used was slightly larger than that used for the wild-type cells to
gain a better understanding of the effect of the concentration on the treatment.

1

2

3

4
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Figure 9. Fluorescent Microscopy of MCF10A p53 (-/-) Cells after
treatment with Alpha Mangostin (1 is the control, 2 is 0.1 μM, 3 is
0.5 μM, 4 is 1 M μM). Blue cells indicate live cells stained with
Hoechst, and green cells indicate apoptotic cells, and red cells
indicate necrotic cells. Increasing concentrations led to a decrease
in live cell count.
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Figure 10. MCF10A p53 (-/-) Alpha Mangostin Dose Response Curve. Cells were treated
with varying concentrations of alpha mangostin for 24 hours and counted using the
fluorescent cell counting program.
In addition to quantitative data, the wells were qualitatively assessed through a
blinded observation to determine the approximate cell viability (Figure 11). It was
important to perform this study for this experiment because the obtained counts for
Figures 9 & 10 were not particularly representative. This is because photos were taken
at the edges of the wells since the middle of the well had limited consistency in all
treatments. Viability was greatly diminished at concentration of 0.25 or greater, which is
in contrast to what was observed with MCF10A wild-type cells.
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Figure 11. Qualitative Observation of Percent Viability for Increasing Treatments of Alpha
Mangostin on MCF10A p53 (-/-) cells. Observations of this percentage were estimated
using a blind study method.
DISCUSSION
Through induction of p53-dependent G2 arrest, pretreatment can prevent cell
death caused by microtubule inhibiting drugs such as paclitaxel. This would allow for
selective killing of p53 mutant cancer cells (Blagosklonny, 2002). In order to assess the
chemoprotective abilities of alpha mangostin, we performed several experiments on
MCF10A wildtype and p53 (-/-) breast cancer cells. When working with this cell line, a
lot of troubleshooting and method alterations went into the process of creating the
experiments. This is important to note because the major time commitment for this
troubleshooting did not allow for duplication of the experiments. In order to fully draw
conclusions from this research, one must duplicate the data in order to gain confidence
in the results presented. Also, it is important to note that the key findings presented in
figure 11 came from a double blinded study to avoid bias.
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To begin, the MCF10A wildtype cells were treated with both alpha mangostin and
paclitaxel separately to create a toxicity and dose response curve in order to determine a
workable range of concentrations for alpha mangostin and an optimum concentration of
paclitaxel for the dual treatment. As shown in figure 4, a 15 nM concentration of paclitaxel
had higher confidence, shown by smaller error bars, and had a significant fraction of less
cells than the 5 nM treatment. The mitogenic effect of lower doses in contrast to the low
number of cells in the control well may be a result of experimental error. This
concentration has the potential to give room for variation of cell number when pretreated
with alpha mangostin. Thus, the 15 nM concentration was chosen to be the fixed
paclitaxel concentration for the dual treatment.
Figure 6 shows that alpha mangostin responds in a dose dependent manner.
These concentrations were shown to be effective to be used for the dual treatments.
Therefore, the next experiment included a dual treatment in which cells were treated
with concentrations of 0.00 μM to 0.25 μM of alpha mangostin on day 1 and treated with
both alpha mangostin and 15 nM paclitaxel on day 2 (Figure 7). The results of this dual
treatment show similar cell counts for cultures treated with and without paclitaxel,
indicating that alpha mangostin is able to effectively protect cells from the normally
cytotoxic effects of paclitaxel. This conclusion is based on the paclitaxel toxicity curve that
shows that adding each subsequent concentration of paclitaxel should decrease cell
number. However, the cells treated with alpha mangostin and no paclitaxel and the cells
that were dual treated had very similar values. Overall, the wells that were pretreated
with alpha mangostin had a much larger live cell count than the well that received no
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alpha mangostin pretreatment before it was treated with paclitaxel (Figure 8). Because
the wild-type cells are also representative of typical human breast cells with wild-type
p53, these experiments indicate that human breast cells will be protected from paclitaxel
by alpha mangostin.
The second section of results evaluates the effect of pretreatment of p53
knockout MCF10A cells to ensure that these cells are not protected by the alpha
mangostin. If the alpha mangostin showed a similar protective effect, then it would not
be a useful selective treatment for breast cancer. To explore the relationship between the
knockout cells and the alpha mangostin, a dose response treatment, ranging from 0 to 1
μM alpha mangostin, was administered to knockout cells for 24 hours (Figure 10). Based
on the mechanism of p53 activators, which includes inhibition of mdm2-p53 interaction
in the normal pathway, cell count numbers were expected to be consistent in different
concentrations of alpha mangostin. However, number of cells decreased with increasing
alpha mangostin concentration. Further analysis revealed that the wells with higher
concentrations of alpha mangostin had many dead cells which were floating and thus not
recognized by the fluorescent microscope. These dead cells indicate that the low number
of cells at high concentrations is not due to cell arrest, but rather from cell toxicity. The
decrease in cell number is shown in Figures 9, 10 and 11. Figure 10 contains quantitative
data that shows a relative decrease in cell number correlates to an increase in
concentration. Figure 11 contains a qualitative observation of percent viability for
increasing treatments of alpha mangostin on MCF10A p53 (-/-) cells. The percent
confluence decreased as alpha mangostin increased. Overall, these data show that the
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number of cells depends on the concentration of the alpha mangostin in a dose
dependent manner.
Overall, the range of concentration of alpha mangostin between 0.1 μM to 0.25
μM showed a protective benefit to wild-type MCF10A breast cancer cells. Furthermore,
the same concentration range decreased cell viability of the MCF10A p53 knockout cell
line. This indicates that alpha mangostin has potential as a selective cancer treatment
when paired with the chemotherapeutic drug paclitaxel. While these results are
encouraging and suggest that alpha mangostin is a potential chemoprotectant for
chemotherapy, it is important to acknowledge the limitations of this research. Due to
difficulties and troubleshooting, only one trial for each of these various treatments was
completed. Therefore, in order to fully validate this research, it must be replicated to
eliminate any results which came from experimental error. Along with replication of this
experiment, it would be beneficial to continue the knockout MCF10A p53 (-/-) study and
perform a toxicity curve with paclitaxel in order to perform a dual treatment study.
Furthermore, these experiments should be performed on several different cell lines to
evaluate the effectiveness of alpha mangostin on different cell types and cancers. Further
research is required to explore the promising pretreatment to chemotherapy, alpha
mangostin.
Although many treatments exist for cancer, scientists are always looking for better
and more effective options for patients. When evaluating treatment plans, patients must
consider both the effectiveness of the treatment and the negative side effects of each
treatment option. While chemotherapy has shown to be an effective and aggressive

20

ALPHA MANGOSTIN AS A CHEMOPROTECTANT
treatment option, it is not selective for that tissue, and therefore has many harsh side
effects including pain, lymphedema, musculoskeletal symptoms, bone loss and
osteoporosis, heart problems, new cancer development, blood clots, infertility, and loss
of memory and cognitive function (American Cancer Society, 2017). This research, as well
as other studies, show that alpha mangostin has potential as a

p53 activation

pretreatment before chemotherapy to limit these side effects.
The p53 gene is a great potential target for cancer treatment because it is the
most frequently altered gene in human cancers (Shibata et al., 2011). If alpha mangostin
can be used as a tool for chemoprotection in a p53-dependent manner in breast cancer
development, then it would enable doctors to treat patients with higher concentrations
of chemotherapy without harming healthy tissue. It would also potentially have
implications in treatments of other types of cancer, such as some uterine, ovarian, and
lung cancers, which also have a high prevalence of p53 mutations. Alpha mangostin offers
a more natural treatment option that can be easily translated to clinical use because it is
already FDA approved. Overall, this study shows that alpha mangostin warrants further
research to better understand its effectiveness as a pretreatment for chemotherapy.
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APPENDIX I
Fluorescent Cell Counting Software Code:
using System;
using System.Collections.Generic;
using System.ComponentModel;
using System.Data;
using System.Drawing;
using System.Linq;
using System.Text;
using System.IO;
using System.Windows.Forms;
namespace Fluorescent_Cell_Counter
{
public partial class Form1 : Form
{
public static Form1 me;
#region Variables
List<Bitmap> bitmaps = new List<Bitmap>();
List<Bitmap> origBitmaps = new List<Bitmap>();
Bitmap bitmap; //used for current one in analysis
List<string> picNames = new List<string>();
List<int[]> results = new List<int[]>();
List<List<Point>> markers = new List<List<Point>>();
List<List<Point>> badMarkers = new List<List<Point>>();
List<List<string>> badMarkersExp = new List<List<string>>();
List<Area> areas = new List<Area>();
Area activeArea = null;
bool defaultArea = false;
int currentPic = 0;
bool analyzing = false;
bool selectingArea = false;
bool mousePressed = false;
int zoomLevel = 0;//0 is normal, 1 is one zoom in, -1 is one zoom out
bool movingSettings = false;
Point settingsOffset;
int analysisMethod = 0; int CUTOFF = 0; int DIFFERENCE = 1;
bool lookingForGreen = true; int GREEN = 0;
bool lookingForRed = false; int RED = 1;
bool lookingForBlue = false; int BLUE = 2;
int colorMinVal = 200;
int graySens = 20;
int whiteSens = 150;
double minCellDist = 12;
double maxCellDist = 45;
int minCellSize = 5;
int maxCellSize = 30;
int pixelSearchRange = 1;
int differenceRange = 10;
int colorDifferenceAmount = 30;
int edgeBuffer = 3;
int defaultAreaSize = 1400;
double cellMult = 1;
double volume = .5;
int pixelScanVal = 2;
#endregion
public Form1()
{
me = this;
InitializeComponent();
timer1.Start();
methodBox.SelectedIndex = 0;
helpPanel.Parent = this;
helpPanel.Location = new Point(230, 68);
}
private void timer1_Tick(object sender, EventArgs e)
{
if (movingSettings)
advancedPanel.Location = new Point(Cursor.Position.X - settingsOffset.X, Cursor.Position.Y - settingsOffset.Y);
if (analyzing || bitmaps.Count == 0 || advancedPanel.Visible == true)
return;
#region Area
if (selectingArea && mousePressed)
{
if (MouseButtons.Equals(MouseButtons.Right))
{
selectingArea = false;
Form1_MouseUp(this, new MouseEventArgs(System.Windows.Forms.MouseButtons.Left, 0, 0, 0, 0));
return;
}
Area a = new Area(this.PointToClient(Cursor.Position), new Point(1, 1));
activeArea = a;
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selectingArea = false;
Form1_MouseUp(this, new MouseEventArgs(System.Windows.Forms.MouseButtons.Left, 0, 0, 0, 0));
return;
}
if (activeArea != null)
{
if (defaultArea)
{
Point apparentSize = new Point((int)(defaultAreaSize * Math.Pow(1.5, zoomLevel)), (int)(defaultAreaSize * Math.Pow(1.5, zoomLevel)));
activeArea.moveArea(new Point(this.PointToClient(Cursor.Position).X - apparentSize.X, this.PointToClient(Cursor.Position).Y - apparentSize.Y), apparentSize);
}
else
{
activeArea.moveArea(activeArea.location, this.PointToClient(Cursor.Position), 0);
}
if (mousePressed)
{
if (MouseButtons.Equals(MouseButtons.Right))
{
selectingArea = false;
activeArea.dispose();
activeArea = null;
defaultArea = false;
Form1_MouseUp(this, new MouseEventArgs(System.Windows.Forms.MouseButtons.Left, 0, 0, 0, 0));
return;
}
if (zoomLevel < 0)
for (int i = zoomLevel; i < 0; i++)
{
activeArea.bitmapLoc = new Point((int)(activeArea.bitmapLoc.X * 1.5), (int)(activeArea.bitmapLoc.Y * 1.5));
activeArea.bitmapSiz = new Point((int)(activeArea.bitmapSiz.X * 1.5), (int)(activeArea.bitmapSiz.Y * 1.5));
}
if (zoomLevel > 0)
for (int i = zoomLevel; i > 0; i--)
{
activeArea.bitmapLoc = new Point((int)(activeArea.bitmapLoc.X * 2 / 3), (int)(activeArea.bitmapLoc.Y * 2 / 3));
activeArea.bitmapSiz = new Point((int)(activeArea.bitmapSiz.X * 2/3), (int)(activeArea.bitmapSiz.Y * 2/3));
}
areas.Add(activeArea);
activeArea = null;
defaultArea = false;
selectingArea = false;
Form1_MouseUp(this, new MouseEventArgs(System.Windows.Forms.MouseButtons.Left, 0, 0, 0, 0));
}
return;
}
#endregion
bool found = false;
#region Regular Markers
foreach (Point m in markers.ElementAt(currentPic))
{
Point loc = this.PointToClient(Cursor.Position);
Point formLoc = loc;
loc.Offset(-pictureBox.Location.X, -pictureBox.Location.Y);
if (zoomLevel < 0)
for (int i = zoomLevel; i < 0; i++)
{
loc = new Point((int)(loc.X * 1.5), (int)(loc.Y * 1.5));
}
if (zoomLevel > 0)
for (int i = zoomLevel; i > 0; i--)
{
loc = new Point((int)(loc.X * 2 / 3), (int)(loc.Y * 2 / 3));
}
if (Math.Abs(m.X - loc.X) < 4 && Math.Abs(m.Y - loc.Y) < 4)
{
found = true;
Point mForm = m;
if (zoomLevel < 0)
for (int i = zoomLevel; i < 0; i++)
{
mForm = new Point((int)(mForm.X * 2 / 3), (int)(mForm.Y * 2 / 3));
}
if (zoomLevel > 0)
for (int i = zoomLevel; i > 0; i--)
{
mForm = new Point((int)(mForm.X * 1.5), (int)(mForm.Y * 1.5));
}
mForm.Offset(pictureBox.Location);
if (highlight.Location != new Point(mForm.X - 4, mForm.Y - 4))
{
highlight.Location = new Point(mForm.X - 4, mForm.Y - 4);
highlight.BringToFront();
}
highlight.Visible = true;
highlight.Show();
highlight.Refresh();
if (mousePressed)
{
int[] i = results.ElementAt(currentPic);
int c = bitmaps.ElementAt(currentPic).GetPixel(m.X, m.Y).ToArgb();
if (c == Color.Red.ToArgb())
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i[GREEN]--;
else if (c == Color.White.ToArgb())
i[RED]--;
else if (c == Color.Orange.ToArgb())
i[BLUE]--;
for (int x = -2; x <= 2; x++)
{
for (int y = -2; y <= 2; y++)
{
if (m.X + x >= 0 && m.X + x < bitmaps.ElementAt(currentPic).Width && m.Y + y >= 0 && m.Y + y < bitmaps.ElementAt(currentPic).Height)
{
Color o = origBitmaps.ElementAt(currentPic).GetPixel(m.X + x, m.Y + y);
bitmaps.ElementAt(currentPic).SetPixel(m.X + x, m.Y + y, o);
}
}
}
pictureBox.Image = bitmaps.ElementAt(currentPic);
pictureBox.Refresh();
markers.ElementAt(currentPic).Remove(m);
results.Insert(currentPic, i);
results.RemoveAt(currentPic + 1);
updateResults();
highlight.Visible = false;
Form1_MouseUp(this, new MouseEventArgs(System.Windows.Forms.MouseButtons.Left, 0, 0, 0, 0));
}
break;
}
}
#endregion
if (!found)
highlight.Visible = false;
}
public void workingAnimation()
{
progressPic.Image.RotateFlip(RotateFlipType.Rotate90FlipNone);
progressPic.Refresh();
}
public void analyze()
{
if (bitmaps.Count == 0)
return;
analyzing = true;
for (int i = 0; i < markers.Count; i++)
{
markers.Insert(i, new List<Point>());
markers.RemoveAt(i + 1);
}
//
for (int i = 0; i < badMarkers.Count; i++)
{
badMarkers.Insert(i, new List<Point>());
badMarkers.RemoveAt(i + 1);
}
for (int i = 0; i < badMarkersExp.Count; i++)
{
badMarkersExp.Insert(i, new List<string>());
badMarkersExp.RemoveAt(i + 1);
}
//
currentPic = 0;
resultBox.Text = "";
for (int i = 0; i < bitmaps.Count; i++)
{
int numGreen = 0;
int numRed = 0;
int numBlue = 0;
resultBox.Text += "Pic " + (i + 1) + " of " + bitmaps.Count + ":" + Environment.NewLine;
if (lookingForGreen)
{
numGreen = maximaMethod(i, GREEN);
resultBox.Text += "Green: " + numGreen + Environment.NewLine;
}
if (lookingForRed)
{
numRed = maximaMethod(i, RED);
resultBox.Text += "Red: " + numRed + Environment.NewLine;
}
if (lookingForBlue)
{
numBlue = maximaMethod(i, BLUE);
resultBox.Text += "Blue: " + numBlue + Environment.NewLine;
}
results.Insert(currentPic, new int[]{numGreen, numRed, numBlue});
results.RemoveAt(currentPic + 1);
pictureBox.Image = bitmaps.ElementAt(currentPic);
pictureBox.Refresh();
if (i != bitmaps.Count - 1)
nextButton_Click(this, new EventArgs());
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}
updateResults();
analyzing = false;
}
public int maximaMethod(int num, int color)
{
List<Point> maxima = new List<Point>();
bitmap = bitmaps.ElementAt(num);
if (areas.Count == 0)
{
for (int x = edgeBuffer; x < bitmap.Width - edgeBuffer; x += pixelScanVal)
{
if (Math.Abs(x % 50) < pixelScanVal)
workingAnimation();
for (int y = edgeBuffer; y < bitmap.Height - edgeBuffer; y += pixelScanVal)
{
if (analysisMethod == CUTOFF)
{
if (pixelRGB(bitmap.GetPixel(x, y), color) >= colorMinVal && !isBadColor(bitmap.GetPixel(x, y), color))
{
maxima.Add(findMaxima(new Point(x, y), color));
}
}
else if (analysisMethod == DIFFERENCE)
{
if (differentEnough(x, y, color) && !isBadColor(bitmap.GetPixel(x, y), color))
{
maxima.Add(findMaxima(new Point(x, y), color));
}
}
}
}
}
else
{
foreach (Area a in areas)
{
for (int x = a.bitmapLoc.X; x < a.bitmapLoc.X + a.bitmapSiz.X; x += pixelScanVal)
{
if (Math.Abs(x % 50) < pixelScanVal)
workingAnimation();
for (int y = a.bitmapLoc.Y; y < a.bitmapLoc.Y + a.bitmapSiz.Y; y += pixelScanVal)
{
if (x < bitmap.Width && y < bitmap.Height)
{
if (analysisMethod == CUTOFF)
{
if (pixelRGB(bitmap.GetPixel(x, y), color) >= colorMinVal && !isBadColor(bitmap.GetPixel(x, y), color))
{
maxima.Add(findMaxima(new Point(x, y), color));
}
}
else if (analysisMethod == DIFFERENCE)
{
if (differentEnough(x, y, color) && !isBadColor(bitmap.GetPixel(x, y), color))
{
maxima.Add(findMaxima(new Point(x, y), color));
}
}
}
}
}
}
}
return cleanMaximaList(maxima, num, color);
}
public int cleanMaximaList(List<Point> maxima, int num, int color)
{
List<Point> maximaNoDup = new List<Point>();
int count = 0;
int pointCount = 0;
foreach (Point p in maxima)
{
bool found = false;
Point toAdd = new Point(-1, -1);
if (pointCount % 50 == 0)
{
workingAnimation();
Application.DoEvents();
}
for (int i = maximaNoDup.Count - 1; i >= 0; i--)
{
if ((p.X - maximaNoDup.ElementAt(i).X) > maxCellDist)
break;
if (p.X == maximaNoDup.ElementAt(i).X && p.Y == maximaNoDup.ElementAt(i).Y)
{
found = true;
break;
}
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if (Math.Sqrt((p.X - maximaNoDup.ElementAt(i).X) * (p.X - maximaNoDup.ElementAt(i).X) + (p.Y - maximaNoDup.ElementAt(i).Y) * (p.Y maximaNoDup.ElementAt(i).Y)) < minCellDist)
{
found = true;
toAdd = p;
break;
}
}
if (toAdd != new Point(-1, -1))
{
maximaNoDup.Add(toAdd);
/*
badMarkers.ElementAt(num).Add(toAdd);
badMarkersExp.ElementAt(num).Add("Too close to other maxima");
for (int x = -2; x <= 2; x++)
{
for (int y = -2; y <= 2; y++)
{
if (p.X + x >= 0 && p.X + x < bitmaps.ElementAt(num).Width && p.Y + y >= 0 && p.Y + y < bitmaps.ElementAt(num).Height)
{
Color c = bitmaps.ElementAt(num).GetPixel(p.X + x, p.Y + y);
if (c != Color.Red && c != Color.White && c != Color.Orange)
bitmaps.ElementAt(num).SetPixel(p.X + x, p.Y + y, Color.Gray);
}
}
}
*/
pointCount++;
continue;
}
if (isBadColor(bitmap.GetPixel(p.X, p.Y), color))
{
/*
badMarkers.ElementAt(num).Add(p);
badMarkersExp.ElementAt(num).Add("Bad color");
for (int x = -2; x <= 2; x++)
{
for (int y = -2; y <= 2; y++)
{
if (p.X + x >= 0 && p.X + x < bitmaps.ElementAt(num).Width && p.Y + y >= 0 && p.Y + y < bitmaps.ElementAt(num).Height)
{
Color c = bitmaps.ElementAt(num).GetPixel(p.X + x, p.Y + y);
if (c != Color.Red && c != Color.White && c != Color.Orange)
bitmaps.ElementAt(num).SetPixel(p.X + x, p.Y + y, Color.Gray);
}
}
}
*/
found = true;
}
if (!bigEnough(p, color))
{
/*
badMarkers.ElementAt(num).Add(p);
badMarkersExp.ElementAt(num).Add("Not big enough");
for (int x = -2; x <= 2; x++)
{
for (int y = -2; y <= 2; y++)
{
if (p.X + x >= 0 && p.X + x < bitmaps.ElementAt(num).Width && p.Y + y >= 0 && p.Y + y < bitmaps.ElementAt(num).Height)
{
Color c = bitmaps.ElementAt(num).GetPixel(p.X + x, p.Y + y);
if (c != Color.Red && c != Color.White && c != Color.Orange)
bitmaps.ElementAt(num).SetPixel(p.X + x, p.Y + y, Color.Gray);
}
}
}
*/
found = true;
}
if (!found)
{
maximaNoDup.Add(p);
Color mColor = new Color();
if (color == GREEN)
mColor = Color.Red;
else if (color == RED)
mColor = Color.White;
else if (color == BLUE)
mColor = Color.Orange;
for (int x = -2; x <= 2; x++)
{
for (int y = -2; y <= 2; y++)
{
if (p.X + x >= 0 && p.X + x < bitmaps.ElementAt(num).Width && p.Y + y >= 0 && p.Y + y < bitmaps.ElementAt(num).Height)
bitmaps.ElementAt(num).SetPixel(p.X + x, p.Y + y, mColor);
}
}
markers.ElementAt(num).Add(p);
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count++;
}
pointCount++;
}
//Console.WriteLine("Count: " + count);
return count;
}
public bool differentEnough(int x, int y, int color)
{
bool diff = false;
for (int n = -differenceRange; n <= differenceRange; n += differenceRange)
{
for (int m = -differenceRange; m <= differenceRange; m += differenceRange)
{
if (n != 0 && m != 0)
continue;
if (x + n >= 0 && x + n < bitmap.Width && y + m >= 0 && y + m < bitmap.Height)
if (pixelRGB(bitmap.GetPixel(x, y), color) >= pixelRGB(bitmap.GetPixel(x + n, y + m), color) + colorDifferenceAmount)
diff = true;
}
}
return diff;
}
public bool bigEnough(Point p, int color)
{
bool enough = false;
int x = p.X;
int y = p.Y;
for (int n = -minCellSize; n <= minCellSize; n += minCellSize)
{
for (int m = -minCellSize; m <= minCellSize; m += minCellSize)
{
if (n != 0 && m != 0)
continue;
if (x + n >= 0 && x + n < bitmap.Width && y + m >= 0 && y + m < bitmap.Height)
{
if (analysisMethod == CUTOFF)
{
if (pixelRGB(bitmap.GetPixel(x + n, y + m), color) >= colorMinVal)
enough = true;
}
else if (analysisMethod == DIFFERENCE)
{
if (pixelRGB(bitmap.GetPixel(x, y), color) >= pixelRGB(bitmap.GetPixel(x + n, y + m), color) + colorDifferenceAmount)
enough = true;
}
}
}
}
return enough;
}
public bool isBadColor(Color c)
{
if (c.R > whiteSens && c.G > whiteSens && c.B > whiteSens)
return true;
if (Math.Abs(c.R - c.G) < graySens && Math.Abs(c.G - c.B) < graySens)
return true;
return false;
}
public bool isBadColor(Color c, int color)
{
if (isBadColor(c))
return true;
if (color == GREEN)
return !(c.G > c.R && c.G > c.B);
if (color == RED)
return !(c.R > c.G && c.R > c.B);
if (color == BLUE)
return !(c.B > c.R && c.B > c.G);
return false;
}
public Point findMaxima(Point p, int color)
{
Point orig = p;
Point lastPoint = p;
Point newPoint = p;
int best = pixelRGB(bitmap.GetPixel(p.X, p.Y), color);
newPt:
for (int x = -pixelSearchRange; x <= pixelSearchRange; x++)
{
for (int y = -pixelSearchRange; y <= pixelSearchRange; y++)
{
p.X = lastPoint.X + x;
p.Y = lastPoint.Y + y;
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if (p.X > 0 && p.X < bitmap.Width && p.Y > 0 && p.Y < bitmap.Height)
{
if (pixelRGB(bitmap.GetPixel(p.X, p.Y), color) > best && !isBadColor(bitmap.GetPixel(p.X, p.Y)))
{
best = pixelRGB(bitmap.GetPixel(p.X, p.Y), color);
newPoint = p;
}
}
}
}
if (Math.Sqrt(Math.Pow(orig.X - lastPoint.X, 2) + Math.Pow(orig.Y - lastPoint.Y, 2)) > maxCellSize)
{
return lastPoint;
}
if (lastPoint != newPoint)
{
lastPoint = newPoint;
goto newPt;
}
return lastPoint;
}
public int pixelRGB(Color c, int color)
{
if (color == GREEN)
return c.G;
if (color == RED)
return c.R;
if (color == BLUE)
return c.B;
return 0;
}
public void updateResults()
{
resultBox.Text = "";
for (int i = 0; i < bitmaps.Count; i++)
{
resultBox.Text += "Pic " + (i + 1) + " of " + bitmaps.Count + ":" + Environment.NewLine;
if (cellMult != 1)
{
if (lookingForGreen || results.ElementAt(i)[GREEN] > 0)
{
resultBox.Text += " Green: " + results.ElementAt(i)[GREEN] + " x" + cellMult + " x" + volume + " = " + (int)(results.ElementAt(i)[GREEN] * cellMult *
volume) + Environment.NewLine;
}
if (lookingForRed || results.ElementAt(i)[RED] > 0)
{
resultBox.Text += " Red: " + results.ElementAt(i)[RED] + " x" + cellMult + " x" + volume + " = " + (int)(results.ElementAt(i)[RED] * cellMult * volume) +
Environment.NewLine;
}
if (lookingForBlue || results.ElementAt(i)[BLUE] > 0)
{
resultBox.Text += " Blue: " + results.ElementAt(i)[BLUE] + " x" + cellMult + " x" + volume + " = " + (int)(results.ElementAt(i)[BLUE] * cellMult * volume)
+ Environment.NewLine;
}
}
else
{
if (lookingForGreen || results.ElementAt(i)[GREEN] > 0)
{
resultBox.Text += " Green: " + results.ElementAt(i)[GREEN] + Environment.NewLine;
}
if (lookingForRed || results.ElementAt(i)[RED] > 0)
{
resultBox.Text += " Red: " + results.ElementAt(i)[RED] + Environment.NewLine;
}
if (lookingForBlue || results.ElementAt(i)[BLUE] > 0)
{
resultBox.Text += " Blue: " + results.ElementAt(i)[BLUE] + Environment.NewLine;
}
}
foreach (Area a in areas)
{
resultBox.Text += " " + a.bitmapSiz.X + " x " + a.bitmapSiz.Y + "px";
}
resultBox.Text += Environment.NewLine;
}
}
public void clearPics()
{
markers = new List<List<Point>>();
badMarkers = new List<List<Point>>();
badMarkersExp = new List<List<string>>();
if (zoomLevel < 0)
for (int i = zoomLevel; i < 0; i++)
zoomInButton_Click(this, new EventArgs());
if (zoomLevel > 0)
for (int i = zoomLevel; i > 0; i--)
zoomOutButton_Click(this, new EventArgs());
pictureBox.Image = null;
pictureBox.Size = new Size(602, 480);
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bitmap = null;
foreach (Bitmap b in bitmaps)
b.Dispose();
bitmaps = new List<Bitmap>();
origBitmaps = new List<Bitmap>();
results = new List<int[]>();
resultBox.Text = "";
resultBox.Location = new Point(pictureBox.Location.X + pictureBox.Size.Width + 6, resultBox.Location.Y);
picNames = new List<string>();
nameBox.Text = "";
currentPic = 0;
prevButton.Enabled = false;
nextButton.Enabled = false;
savePicsButton.Enabled = false;
clearAreaButton_Click(this, new EventArgs());
}
#region Form Stuff
public void Form1_MouseDown(object sender, MouseEventArgs e)
{
mousePressed = true;
}
private void Form1_MouseUp(object sender, MouseEventArgs e)
{
mousePressed = false;
}
private void pictureBox_Click(object sender, EventArgs e)
{
if (selectingArea || bitmaps.Count == 0 || activeArea != null)
return;
int[] r = results.ElementAt(currentPic);
Color mColor = new Color();
if (lookingForGreen)
{
r[GREEN]++;
mColor = Color.Red;
}
else if (lookingForRed)
{
r[RED]++;
mColor = Color.White;
}
else if (lookingForBlue)
{
r[BLUE]++;
mColor = Color.Orange;
}
Point loc = this.PointToClient(Cursor.Position);
loc.Offset(-pictureBox.Location.X, -pictureBox.Location.Y);
if (zoomLevel < 0)
for (int i = zoomLevel; i < 0; i++)
{
loc = new Point((int)(loc.X * 1.5), (int)(loc.Y * 1.5));
}
if (zoomLevel > 0)
for (int i = zoomLevel; i > 0; i--)
{
loc = new Point((int)(loc.X * 2 / 3), (int)(loc.Y * 2 / 3));
}
for (int x = -2; x <= 2; x++)
{
for (int y = -2; y <= 2; y++)
{
if (loc.X + x >= 0 && loc.X + x < bitmaps.ElementAt(currentPic).Width && loc.Y + y >= 0 && loc.Y + y < bitmaps.ElementAt(currentPic).Height)
bitmaps.ElementAt(currentPic).SetPixel(loc.X + x, loc.Y + y, mColor);
}
}
markers.ElementAt(currentPic).Add(loc);
results.Insert(currentPic, r);
results.RemoveAt(currentPic + 1);
updateResults();
}
private void progressPic_Click(object sender, EventArgs e)
{
OpenFileDialog ofile = new OpenFileDialog();
ofile.Filter = "Image File (*.bmp, *.jpg, *.png)|*.bmp;*.jpg;*.png";
if (DialogResult.OK == ofile.ShowDialog())
{
progressPic.Image = new Bitmap(ofile.FileName);
}
}
private void advancedPanel_MouseDown(object sender, MouseEventArgs e)
{
movingSettings = true;
settingsOffset = new Point(Cursor.Position.X - advancedPanel.Location.X, Cursor.Position.Y - advancedPanel.Location.Y);
}
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private void advancedPanel_MouseUp(object sender, MouseEventArgs e)
{
movingSettings = false;
}
#endregion
#region Main Buttons
private void selectPicButton_Click(object sender, EventArgs e)
{
OpenFileDialog ofile = new OpenFileDialog();
ofile.Multiselect = true;
ofile.Filter = "Image File (*.bmp, *.jpg, *.png)|*.bmp;*.jpg;*.png";
if (DialogResult.OK == ofile.ShowDialog())
{
clearPics();
foreach (String file in ofile.FileNames)
{
bitmaps.Add(new Bitmap(file));
origBitmaps.Add(new Bitmap(file));
picNames.Add(file);
markers.Add(new List<Point>());
badMarkers.Add(new List<Point>());
badMarkersExp.Add(new List<string>());
results.Add(new int[]{0, 0, 0});
}
pictureBox.Image = bitmaps.ElementAt(0);
pictureBox.Size = new System.Drawing.Size(pictureBox.Image.Width, pictureBox.Image.Height);
nameBox.Text = "1 of " + bitmaps.Count + ": " + picNames.ElementAt(0);
bitmap = bitmaps.ElementAt(0);
resultBox.Location = new Point(pictureBox.Location.X + pictureBox.Size.Width + 6, resultBox.Location.Y);
}
if (bitmaps.Count > 1)
{
prevButton.Enabled = true;
nextButton.Enabled = true;
}
else
{
prevButton.Enabled = false;
nextButton.Enabled = false;
}
savePicsButton.Enabled = false;
}
private void analyzeButton_Click(object sender, EventArgs e)
{
if (bitmaps.Count == 0)
return;
bitmaps = new List<Bitmap>();
foreach (Bitmap b in origBitmaps)
bitmaps.Add(new Bitmap(b));
analyze();
savePicsButton.Enabled = true;
}
private void clearButton_Click(object sender, EventArgs e)
{
clearPics();
}
private void prevButton_Click(object sender, EventArgs e)
{
int thisZoom = zoomLevel;
if (bitmaps.Count == 0)
return;
//last pic regular zoom
if (zoomLevel < 0)
for (int i = zoomLevel; i < 0; i++)
zoomInButton_Click(this, new EventArgs());
if (zoomLevel > 0)
for (int i = zoomLevel; i > 0; i--)
zoomOutButton_Click(this, new EventArgs());
if (currentPic == 0)
currentPic = bitmaps.Count - 1;
else
currentPic--;
//new pic preferred zoom
pictureBox.Image = bitmaps.ElementAt(currentPic);
pictureBox.Size = new System.Drawing.Size(pictureBox.Image.Width, pictureBox.Image.Height);
zoomLevel = 0;
if (thisZoom < 0)
for (int i = thisZoom; i < 0; i++)
zoomOutButton_Click(this, new EventArgs());
if (thisZoom > 0)
for (int i = thisZoom; i > 0; i--)
zoomInButton_Click(this, new EventArgs());
nameBox.Text = (currentPic + 1) + " of " + bitmaps.Count + ": " + picNames.ElementAt(currentPic);
resultBox.Location = new Point(pictureBox.Location.X + pictureBox.Size.Width + 6, resultBox.Location.Y);
}

32

ALPHA MANGOSTIN AS A CHEMOPROTECTANT
private void nextButton_Click(object sender, EventArgs e)
{
int thisZoom = zoomLevel;
if (bitmaps.Count == 0)
return;
//last pic regular zoom
if (zoomLevel < 0)
for (int i = zoomLevel; i < 0; i++)
zoomInButton_Click(this, new EventArgs());
if (zoomLevel > 0)
for (int i = zoomLevel; i > 0; i--)
zoomOutButton_Click(this, new EventArgs());
if (currentPic == bitmaps.Count - 1)
currentPic = 0;
else
currentPic++;
//new pic preferred zoom
pictureBox.Image = bitmaps.ElementAt(currentPic);
pictureBox.Size = new System.Drawing.Size(pictureBox.Image.Width, pictureBox.Image.Height);
zoomLevel = 0;
pictureBox.Refresh();
pictureBox.Show();
if (thisZoom < 0)
for (int i = thisZoom; i < 0; i++)
zoomOutButton_Click(this, new EventArgs());
if (thisZoom > 0)
for (int i = thisZoom; i > 0; i--)
zoomInButton_Click(this, new EventArgs());
nameBox.Text = (currentPic + 1) + " of " + bitmaps.Count + ": " + picNames.ElementAt(currentPic);
nameBox.Refresh();
nameBox.Show();
resultBox.Location = new Point(pictureBox.Location.X + pictureBox.Size.Width + 6, resultBox.Location.Y);
}
private void zoomInButton_Click(object sender, EventArgs e)
{
if (analyzing || bitmaps.Count == 0)
return;
pictureBox.Size = new Size((int)(pictureBox.Size.Width * 1.5), (int)(pictureBox.Size.Height * 1.5));
resultBox.Location = new Point(pictureBox.Location.X + pictureBox.Size.Width + 6, resultBox.Location.Y);
foreach (Area a in areas)
{
Point p = new Point(a.location.X - pictureBox.Location.X, a.location.Y - pictureBox.Location.Y);
p = new Point((int)(p.X * 1.5), (int)(p.Y * 1.5));
p = new Point(p.X + pictureBox.Location.X, p.Y + pictureBox.Location.Y);
a.zoomArea(p, new Point((int)(a.size.X * 1.5), (int)(a.size.Y * 1.5)));
}
zoomLevel++;
}
private void zoomOutButton_Click(object sender, EventArgs e)
{
if (analyzing || bitmaps.Count == 0)
return;
pictureBox.Size = new Size((int)(pictureBox.Size.Width * 2 / 3), (int)(pictureBox.Size.Height * 2 / 3));
resultBox.Location = new Point(pictureBox.Location.X + pictureBox.Size.Width + 6, resultBox.Location.Y);
foreach (Area a in areas)
{
Point p = new Point(a.location.X - pictureBox.Location.X, a.location.Y - pictureBox.Location.Y);
p = new Point((int)(p.X * 2 / 3), (int)(p.Y * 2 / 3));
p = new Point(p.X + pictureBox.Location.X, p.Y + pictureBox.Location.Y);
a.zoomArea(p, new Point((int)(a.size.X * 2 / 3), (int)(a.size.Y * 2 / 3)));
}
zoomLevel--;
}
private void advancedButton_Click(object sender, EventArgs e)
{
advancedPanel.Visible = true;
advancedPanel.BringToFront();
advancedInfoBox.Text = "";
greenCheckBox.Checked = lookingForGreen;
redCheckBox.Checked = lookingForRed;
blueCheckBox.Checked = lookingForBlue;
greenValEntry.Text = colorMinVal + "";
minCellDistEntry.Text = minCellDist + "";
pixelSearchDistEntry.Text = pixelSearchRange + "";
whiteSensEntry.Text = whiteSens + "";
graySensEntry.Text = graySens + "";
maxCellDistEntry.Text = maxCellDist + "";
colorDiffRangeBox.Text = differenceRange + "";
greenDiffAmountBox.Text = colorDifferenceAmount + "";
minCellSizeBox.Text = minCellSize + "";
edgeBufferBox.Text = edgeBuffer + "";
defaultAreaSizeBox.Text = defaultAreaSize + "";
cellMultiplierBox.Text = cellMult + "";
totalVolBox.Text = volume + "";
maxCellSizeBox.Text = maxCellSize + "";
pixelScanEntry.Text = pixelScanVal + "";
}
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private void areaButton_Click(object sender, EventArgs e)
{
if (analyzing || bitmaps.Count == 0)
return;
selectingArea = true;
}
private void clearAreaButton_Click(object sender, EventArgs e)
{
foreach (Area a in areas)
a.dispose();
areas = new List<Area>();
}
private void defaultAreaButton_Click(object sender, EventArgs e)
{
if (analyzing || bitmaps.Count == 0)
return;
defaultArea = true;
//activeArea = new Area(new Point(this.PointToClient(Cursor.Position).X, this.PointToClient(Cursor.Position).Y), new Point(defaultAreaSize, defaultAreaSize));
activeArea = new Area(new Point(this.PointToClient(Cursor.Position).X - (int)(defaultAreaSize / 1), this.PointToClient(Cursor.Position).Y - (int)(defaultAreaSize / 1)),
new Point((int)(defaultAreaSize * Math.Pow(1.5, zoomLevel)), (int)(defaultAreaSize * Math.Pow(1.5, zoomLevel))));
}
private void mainHelpButton_Click(object sender, EventArgs e)
{
helpPanel.Visible = !helpPanel.Visible;
helpPanel.BringToFront();
}
private void savePicsButton_Click(object sender, EventArgs e)
{
if (results.Count != bitmaps.Count)
{
MessageBox.Show("Please run the analysis to save pictures");
return;
}
string path = "";
FolderBrowserDialog fbd = new FolderBrowserDialog();
fbd.SelectedPath = picNames.ElementAt(0).Substring(0, picNames.ElementAt(0).LastIndexOf("\\"));
DialogResult result = fbd.ShowDialog();
if (result == DialogResult.OK && !string.IsNullOrWhiteSpace(fbd.SelectedPath))
{
path = fbd.SelectedPath;
for (int i = 0; i < bitmaps.Count; i++)
{
int start = picNames.ElementAt(i).LastIndexOf("\\");
int end = picNames.ElementAt(i).Length - 4;
bitmaps.ElementAt(i).Save(path + picNames.ElementAt(i).Substring(start, end - start) + "-" + results.ElementAt(i).Sum() + ".png",
System.Drawing.Imaging.ImageFormat.Png);
workingAnimation();
}
if (bitmaps.Count == 1)
MessageBox.Show("Picture successfully saved");
else
MessageBox.Show("Pictures successfully saved");
}
}
#endregion
#region Settings Buttons
private void advancedAcceptButton_Click(object sender, EventArgs e)
{
advancedPanel.Visible = false;
lookingForGreen = greenCheckBox.Checked;
lookingForRed = redCheckBox.Checked;
lookingForBlue = blueCheckBox.Checked;
saveValues();
}
private void advancedCancelButton_Click(object sender, EventArgs e)
{
advancedPanel.Visible = false;
}
private void greenValEntry_KeyDown(object sender, KeyEventArgs e)
{
if (e.KeyCode == Keys.Enter)
{
advancedAcceptButton_Click(this, new EventArgs());
}
}
private void methodBox_SelectedIndexChanged(object sender, EventArgs e)
{
analysisMethod = methodBox.SelectedIndex;
if (analysisMethod == CUTOFF)
{
colorDiffRangeBox.ReadOnly = true;
greenDiffAmountBox.ReadOnly = true;
greenValEntry.ReadOnly = false;
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}
else if (analysisMethod == DIFFERENCE)
{
colorDiffRangeBox.ReadOnly = false;
greenDiffAmountBox.ReadOnly = false;
greenValEntry.ReadOnly = true;
}
}
private void methodInfoButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "The Cutoff method detects cells based on the amount of color they have. The Difference method detects cells based on the difference in color
between them and their surroundings.";
}
private void greenValHelp_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Only 0-255) If your background is closer to the cell color, set this higher so the program doesn't see the background as a cell. If your cells are a
dimmer color, set this lower to detect them.";
}
private void graySensButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Only 0-255) This keeps gray colors from being recognized as cells. If your cells are grayer in color, this may need to be lowered.";
}
private void whiteSensButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Only 0-255) This keeps white colors from being recognized as cells. Raise this number for whiter cells, lower it to keep from counting non-cell
white spots.";
}
private void pixelScanButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Suggested 1 - 4) This is how closely the program searches the pixels. Higher numbers greatly speed up the program. Lower numbers needed
for very small cells or low resolution images.";
}
private void minCellDistButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Suggested 5-20) This keeps the program from seeing one cell as multiple. If your cells are close together, make this small; if your cells are
farther apart, make this larger";
}
private void maxCellDistButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Suggested 15-60) This lets the program run more quickly. Smaller = Faster. Should be at least 3X the Min Cell Distance.";
}
private void minCellSizeButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Suggested 2-10) This keeps the program from seeing small specks as cells. If your cells are bigger or small specks are being detected, make this
bigger. If your cells are smaller, make this smaller.";
}
private void pixelSearchDistButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Suggested 1-3) If your picture is more grainy, make this bigger, but usually 1 works fine. Bigger numbers make the program slower.";
}
private void colorDiffRangeButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Suggested 5-15) If your cells are closer together or have fine edges, make this smaller. If your cells are more spread out or have fuzzy edges,
make this larger.";
}
private void greenDiffAmountButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Only 0-255) If your cells are more similar in color to the background, make this smaller.";
}
private void edgeBufferButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "(Suggested 0-5) This gets rid of small blips on the edge or picture borders being seen as cells. If there are incorrect edge counts, make this larger.
If cells on the edge aren't being detected, make this smaller.";
}
private void defaultAreaSizeButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "This is the size of the default area that can be placed, in pixels.";
}
private void cellMultiplierButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "The number to multiply the number of cells by for recording data.";
}
private void totalVolButton_Click(object sender, EventArgs e)
{
advancedInfoBox.Text = "This number is used to multiply the number of cells for recording data.";
}
private void maxCellSizeButton_Click(object sender, EventArgs e)
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{
advancedInfoBox.Text = "(Suggested 25-50) This keeps the program from seeing masses of cells as 1 cell. If your cells are bigger, make this bigger. If your cells are
smaller, make this smaller.";
}
private void saveSettingsButton_Click(object sender, EventArgs e)
{
SaveFileDialog sfile = new SaveFileDialog();
sfile.Filter = "Text File (*.txt)|*.txt";
if (DialogResult.OK == sfile.ShowDialog() && sfile.FileName != "")
{
saveValues();
using (StreamWriter writer = new StreamWriter(sfile.OpenFile()))
{
writer.Write(colorMinVal + "," + graySens + "," + whiteSens + "," + minCellDist + "," + maxCellDist + "," +
minCellSize + "," + maxCellSize + "," + pixelSearchRange + "," + differenceRange + "," + colorDifferenceAmount
+ "," + edgeBuffer + "," + defaultAreaSize + "," + cellMult + "," + volume + "," + pixelScanVal);
writer.Dispose();
writer.Close();
}
int index = sfile.FileName.LastIndexOf("\\");
savedSettingsLabel.Text = sfile.FileName.Substring(index + 1);
}
}
private void loadSettingsButton_Click(object sender, EventArgs e)
{
OpenFileDialog ofile = new OpenFileDialog();
ofile.Multiselect = false;
ofile.Filter = "Text File (*.txt)|*.txt";
if (DialogResult.OK == ofile.ShowDialog())
{
String str = System.IO.File.ReadAllText(ofile.FileName);
int index = str.IndexOf(",");
colorMinVal = Int32.Parse(str.Substring(0, index));
greenValEntry.Text = colorMinVal + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
graySens = Int32.Parse(str.Substring(0, index));
graySensEntry.Text = graySens + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
whiteSens = Int32.Parse(str.Substring(0, index));
whiteSensEntry.Text = whiteSens + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
minCellDist = Int32.Parse(str.Substring(0, index));
minCellDistEntry.Text = minCellDist + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
maxCellDist = Int32.Parse(str.Substring(0, index));
maxCellDistEntry.Text = maxCellDist + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
minCellSize = Int32.Parse(str.Substring(0, index));
minCellSizeBox.Text = minCellSize + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
maxCellSize = Int32.Parse(str.Substring(0, index));
maxCellSizeBox.Text = maxCellSize + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
pixelSearchRange = Int32.Parse(str.Substring(0, index));
pixelSearchDistEntry.Text = pixelSearchRange + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
differenceRange = Int32.Parse(str.Substring(0, index));
colorDiffRangeBox.Text = differenceRange + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
colorDifferenceAmount = Int32.Parse(str.Substring(0, index));
greenDiffAmountBox.Text = colorDifferenceAmount + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
edgeBuffer = Int32.Parse(str.Substring(0, index));
edgeBufferBox.Text = edgeBuffer + "";
str = str.Substring(index + 1);
index = str.IndexOf(",");
defaultAreaSize = Int32.Parse(str.Substring(0, index));
defaultAreaSizeBox.Text = defaultAreaSize + "";
str = str.Substring(index + 1);
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index = str.IndexOf(",");
cellMult = Int32.Parse(str.Substring(0, index));
cellMultiplierBox.Text = cellMult + "";
str = str.Substring(index + 1);
if (str.IndexOf(",") == -1)
{
volume = Double.Parse(str);
totalVolBox.Text = volume + "";
pixelScanVal = 2;
goto done;
}
index = str.IndexOf(",");
volume = Double.Parse(str.Substring(0, index));
totalVolBox.Text = volume + "";
str = str.Substring(index + 1);
if (str.IndexOf(",") == -1)
{
pixelScanVal = Int32.Parse(str);
pixelScanEntry.Text = pixelScanVal + "";
goto done;
}
index = str.IndexOf(",");
pixelScanVal = Int32.Parse(str.Substring(0, index));
pixelScanEntry.Text = pixelScanVal + "";
str = str.Substring(index + 1);
//Add additional setting vals here
done:
index = ofile.FileName.LastIndexOf("\\");
savedSettingsLabel.Text = ofile.FileName.Substring(index + 1);
}
}
private void saveValues()
{
colorMinVal = Convert.ToInt32(greenValEntry.Text);
minCellDist = Convert.ToDouble(minCellDistEntry.Text);
pixelSearchRange = Convert.ToInt32(pixelSearchDistEntry.Text);
whiteSens = Convert.ToInt32(whiteSensEntry.Text);
graySens = Convert.ToInt32(graySensEntry.Text);
maxCellDist = Convert.ToDouble(maxCellDistEntry.Text);
differenceRange = Convert.ToInt32(colorDiffRangeBox.Text);
colorDifferenceAmount = Convert.ToInt32(greenDiffAmountBox.Text);
minCellSize = Convert.ToInt32(minCellSizeBox.Text);
edgeBuffer = Convert.ToInt32(edgeBufferBox.Text);
defaultAreaSize = Convert.ToInt32(defaultAreaSizeBox.Text);
cellMult = Convert.ToDouble(cellMultiplierBox.Text);
volume = Convert.ToDouble(totalVolBox.Text);
maxCellSize = Convert.ToInt32(maxCellSizeBox.Text);
pixelScanVal = Convert.ToInt32(pixelScanEntry.Text);
}
#endregion
}
class Area
{
public Point location;
public Point size;
public Point bitmapLoc;
public Point bitmapSiz;
public Label top;
public Label bottom;
public Label left;
public Label right;
public Area()
{
}
public Area(Point loc, Point siz)
{
location = loc;
size = siz;
top = new Label();
bottom = new Label();
left = new Label();
right = new Label();
List<Label> list = new List<Label>{top, bottom, left, right};
foreach (Label l in list)
{
l.BackColor = Color.Orange;
l.Text = "";
l.AutoSize = false;
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l.Parent = Form1.ActiveForm;
l.BorderStyle = BorderStyle.None;
l.Visible = true;
l.MouseDown += new MouseEventHandler(Form1.me.Form1_MouseDown);
}
redoLocSize(true);
}
public Area(Point upperLeft, Point lowerRight, int nothing) :
this(upperLeft, new Point(lowerRight.X - upperLeft.X, lowerRight.Y - upperLeft.Y))
{
}
public void moveArea(Point loc, Point siz)
{
location = loc;
size = siz;
redoLocSize(true);
}
public void moveArea(Point upperLeft, Point lowerRight, int nothing)
{
moveArea(upperLeft, new Point(lowerRight.X - upperLeft.X, lowerRight.Y - upperLeft.Y));
}
public void zoomArea(Point loc, Point siz)
{
location = loc;
size = siz;
redoLocSize(false);
}
private void redoLocSize(bool doIt)
{
if (doIt)
{
bitmapLoc = new Point(location.X - Form1.me.pictureBox.Location.X, location.Y - Form1.me.pictureBox.Location.Y);
bitmapSiz = size;
}
if (size.X >= 0)
{
if (size.Y >= 0)
{
top.Location = new Point(location.X - 6, location.Y - 6);
left.Location = new Point(location.X - 6, location.Y - 6);
bottom.Location = new Point(location.X - 6, location.Y + size.Y);
right.Location = new Point(location.X + size.X, location.Y - 6);
}
else
{
top.Location = new Point(location.X - 6, location.Y + size.Y - 6);
left.Location = new Point(location.X - 6, location.Y + size.Y - 6);
bottom.Location = new Point(location.X - 6, location.Y);
right.Location = new Point(location.X + size.X, location.Y + size.Y - 6);
location = new Point(location.X, location.Y + size.Y);
}
}
else
{
if (size.Y >= 0)
{
top.Location = new Point(location.X + size.X - 6, location.Y - 6);
left.Location = new Point(location.X + size.X - 6, location.Y - 6);
bottom.Location = new Point(location.X + size.X - 6, location.Y + size.Y);
right.Location = new Point(location.X, location.Y - 6);
location = new Point(location.X + size.X, location.Y);
}
else
{
top.Location = new Point(location.X + size.X - 6, location.Y + size.Y - 6);
left.Location = new Point(location.X + size.X - 6, location.Y + size.Y - 6);
bottom.Location = new Point(location.X + size.X - 6, location.Y);
right.Location = new Point(location.X, location.Y + size.Y - 6);
location = new Point(location.X + size.X, location.Y + size.Y);
}
}
size = new Point(Math.Abs(size.X), Math.Abs(size.Y));
top.Size = new Size(Math.Abs(size.X) + 12, 6);
bottom.Size = new Size(Math.Abs(size.X) + 12, 6);
right.Size = new Size(6, Math.Abs(size.Y) + 12);
left.Size = new Size(6, Math.Abs(size.Y) + 12);
top.BringToFront();
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bottom.BringToFront();
left.BringToFront();
right.BringToFront();
}
public void dispose()
{
top.Dispose();
bottom.Dispose();
left.Dispose();
right.Dispose();
}
}
}
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